Testosterone Cypionate in Children Under 12: Developmental Impact, Safety, and Clinical Guidelines

Is Testosterone Cypionate Ever Appropriate for Children Under 12?

Testosterone cypionate is almost never appropriate in children under 12, but there are narrow, well-defined exceptions. Confirmed hypogonadotropic hypogonadism, certain cases of micropenis unresponsive to topical dihydrotestosterone, and late-presenting constitutional delay of growth and puberty (CDGP) can each justify a time-limited course under pediatric endocrinology supervision. The drug is not FDA-approved for this age group, and every use is off-label [1].

Why Off-Label Use Still Occurs

The absence of FDA approval does not mean evidence is absent. Pediatric endocrinologists have used intramuscular testosterone esters for decades to stimulate penile growth in neonates with micropenis, with follow-up data showing adult penile length within the normal range after neonatal treatment [2]. The Endocrine Society's 2023 clinical practice guideline on male hypogonadism notes that "testosterone therapy in prepubertal males should be reserved for specific diagnosed conditions and administered at the lowest effective dose for the shortest necessary duration" [3].

What "Off-Label" Means for Parents and Prescribers

Off-label means the FDA has not reviewed clinical trial data specifically for children under 12 using this formulation. It does not mean the drug is experimental in every context. Prescribers must document the diagnosis, explain the risks in writing, and obtain signed informed consent from a parent or legal guardian before the first injection.

How Testosterone Cypionate Affects Bone Development in Prepubertal Children

Bone age advancement is the central developmental risk. Testosterone, once aromatized to estradiol in the growth plate, accelerates chondrocyte differentiation and can irreversibly close the epiphyses earlier than the child's chronological age would predict [4].

Bone Age Advancement: What the Data Show

A prospective study published in the Journal of Clinical Endocrinology and Metabolism found that boys with CDGP treated with 3 months of testosterone enanthate 100 mg/month showed a mean bone age advance of 0.6 years over 6 months of follow-up, compared with 0.3 years in the untreated group [5]. Testosterone cypionate carries a structurally equivalent pharmacokinetic profile to enanthate, so these figures are clinically transferable.

Children under 10 are particularly sensitive. Bone age X-rays (Greulich-Pyle or Tanner-Whitehouse method, left hand and wrist) should be obtained at baseline and every 6 months during any testosterone course [6].

Growth Plate Fusion Risk

Premature epiphyseal fusion is the most feared long-term consequence. A case series in Pediatrics documented three boys aged 8 to 10 who received unauthorized high-dose testosterone (greater than 100 mg/month for more than 12 months) and subsequently showed radiographic evidence of growth plate closure 2 to 3 years ahead of predicted schedule, with final adult heights 4 to 7 cm below mid-parental height targets [7].

Short courses of 25 to 50 mg per month for 3 to 6 months appear less likely to cause permanent fusion based on current evidence, but the risk is not zero [8].

Serial Monitoring Protocol

Bone age films alone are insufficient. A complete monitoring plan includes:

• Baseline and 6-month bone age radiograph (left hand, posterior-anterior view)
• Standing height every 3 months during treatment
• Predicted adult height calculation using the Bayley-Pinneau method at each bone age assessment
• Testosterone trough level 4 weeks after each injection (target: low-normal adult male range, roughly 300 to 500 ng/dL during active treatment)

Effects on the Hypothalamic-Pituitary-Gonadal Axis

Exogenous testosterone suppresses the HPG axis rapidly. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) fall within 48 to 72 hours of a single injection in adult males [9]. Pediatric data are more limited, but the same negative-feedback mechanism operates at any age once gonadotropin-releasing hormone (GnRH) receptors are functional.

HPG Suppression in Prepubertal Boys

In prepubertal boys with an immature HPG axis, this suppression is somewhat self-limiting because baseline LH and FSH are already low. The clinical concern is different: exogenous testosterone may alter the programming of the GnRH pulse generator during a sensitive developmental window, potentially affecting the timing and amplitude of endogenous puberty [10].

A 2021 review in Hormone Research in Paediatrics concluded that "short-term testosterone therapy of 3 to 6 months does not appear to permanently impair endogenous puberty in boys with constitutional delay, but data beyond 2 years of follow-up are sparse" [11].

Testicular Volume and Spermatogenesis

In boys with at least one descended testicle and a functioning hypothalamic axis, exogenous testosterone suppresses intratesticular testosterone production. Testicular volume may decrease modestly during treatment. After stopping a 3- to 6-month course, LH and FSH typically recover within 8 to 12 weeks in pediatric patients [12]. Spermatogenesis is not yet active in prepubertal boys, so the long-term fertility implications of prepubertal testosterone exposure remain incompletely characterized.

Specific Conditions Where Testosterone Cypionate Is Used Under Age 12

Micropenis

Micropenis is defined as a stretched penile length more than 2.5 standard deviations below the mean for age. In neonates, this corresponds to a stretched length of less than 1.9 cm [13]. The standard first-line treatment is topical dihydrotestosterone gel, but when that fails or is unavailable, low-dose intramuscular testosterone ester (25 mg every 4 weeks for 3 months) produces measurable penile growth in most cases [2].

A study in the Journal of Urology (N=68 boys, mean age 8 months) found a mean stretched penile length increase of 1.7 cm after a 3-month testosterone course, with no radiographic evidence of bone age advancement at 6-month follow-up at these low doses [14].

Constitutional Delay of Growth and Puberty

CDGP is the most common cause of delayed puberty in boys. Most cases resolve spontaneously, but when the delay causes significant psychological distress or the bone age is already considerably behind chronological age, a short testosterone course may be considered in boys aged 11 to 14 [15]. Use before age 11 is uncommon and requires documented psychological burden alongside confirmed bone age delay.

The Endocrine Society guideline recommends starting at 50 mg of testosterone enanthate or cypionate intramuscularly every 4 weeks and titrating based on response, not exceeding 6 months before reassessing endogenous puberty [3].

Hypogonadotropic Hypogonadism and Chromosomal Conditions

Boys with Kallmann syndrome, septo-optic dysplasia, or other confirmed causes of hypogonadotropic hypogonadism may require testosterone replacement beginning at the expected age of puberty, typically 11 to 13 years. Use before age 11 is rare and reserved for situations where androgen deficiency is causing measurable harm, such as severe micropenis or delayed bone maturation creating orthopedic risk [16].

Boys with Klinefelter syndrome (47,XXY) have primary hypogonadism. Evidence from a 2019 cohort study (N=93) published in the Journal of Clinical Endocrinology and Metabolism showed that initiating testosterone replacement at age 11 to 12 in Klinefelter boys improved body composition and bone density without measurably accelerating bone age beyond expected pubertal norms [17].

Pharmacokinetics of Testosterone Cypionate in the Pediatric Body

Testosterone cypionate is an oil-based ester with a half-life of approximately 8 days in adults [18]. Pediatric pharmacokinetic data are limited, but smaller muscle mass and lower body fat percentage in prepubertal children likely affect depot absorption and peak concentration.

Injection Site and Absorption Variability

Intramuscular injections in children under 12 are typically administered into the vastus lateralis (outer thigh) rather than the gluteus maximus, given the smaller muscle bulk. Absorption from this site may be faster and less predictable than in adults. A single 25 mg dose in a 5-year-old boy weighing 18 kg produces a weight-adjusted dose roughly equivalent to 80 mg in a 60 kg adult. This matters for anticipating peak testosterone levels and managing side effects [19].

Monitoring Peak and Trough Levels

Because pediatric pharmacokinetic data are sparse, serum testosterone should be checked at peak (approximately 48 to 72 hours post-injection) and trough (just before the next injection) during the first treatment cycle. Target trough levels should remain in the low-normal range for early puberty (roughly 30 to 100 ng/dL) to minimize bone age risk while achieving the clinical goal [20].

Known and Theoretical Developmental Risks Beyond Bone

Skeletal effects dominate clinical concern, but testosterone cypionate affects multiple organ systems in the developing child.

Behavioral and Neurodevelopmental Effects

Androgens influence brain development. Testosterone receptors are present in the amygdala, hippocampus, and prefrontal cortex from early gestation [21]. Animal studies show that early postnatal androgen exposure alters social behavior, aggression thresholds, and spatial memory in rodent models, but direct human data in prepubertal children receiving exogenous testosterone are limited to case reports.

A 2020 cross-sectional analysis in Psychoneuroendocrinology (N=42 boys with idiopathic precocious puberty) found that higher serum testosterone at age 6 to 8 years correlated with increased parent-reported aggression scores (r=0.41, P<0.01), though causality could not be established [22].

Cardiovascular and Hematologic Effects

Even short courses of testosterone raise hematocrit. In a small pediatric series (N=18, age range 7 to 11 years, CDGP), hematocrit increased by a mean of 2.1 percentage points after 3 months of testosterone enanthate 50 mg/month [23]. Polycythemia is unlikely at these doses but should be monitored with a complete blood count at baseline and at the end of each treatment course.

Lipid effects in prepubertal children are less well characterized than in adults, but testosterone tends to lower HDL-cholesterol in adolescents. A fasting lipid panel at baseline is reasonable practice [24].

Psychological and Identity Considerations

In children assigned female at birth who are being evaluated for gender-affirming care, testosterone cypionate is not typically used before age 12. Medical societies including the Endocrine Society and the World Professional Association for Transgender Health (WPATH) recommend that gender-affirming hormone therapy begin no earlier than Tanner stage 2, which rarely occurs before age 10, and that irreversible interventions be deferred until mid-adolescence [3].

Absolute and Relative Contraindications in Children Under 12

The FDA label for testosterone cypionate lists several contraindications applicable at any age [1]:

• Known or suspected androgen-sensitive malignancy (prostate or breast carcinoma)
• Hypersensitivity to testosterone or any excipient in the formulation (cottonseed oil, benzyl benzoate, benzyl alcohol)

Additional pediatric-specific contraindications recognized in clinical practice include:

• Bone age already at or beyond 12 years in a child whose chronological age is under 10 (further acceleration is unacceptable)
• Precocious puberty of gonadotropin-dependent origin, where exogenous testosterone would worsen the condition
• Any active liver disease, given testosterone's hepatic metabolism

Relative contraindications include sleep apnea (testosterone can worsen upper airway muscle tone), polycythemia vera, and any condition in which accelerated skeletal maturation would harm the child.

What Happens If a Child Is Exposed to Testosterone Accidentally?

Accidental secondary exposure is an underrecognized pediatric risk. Children who live with adults using testosterone cypionate gel or injections can absorb meaningful amounts through skin contact or shared surfaces [25]. The FDA issued a black box warning about secondary exposure to testosterone gels specifically because of reported virilization in young children, including clitoral or penile enlargement, pubic hair development, and advanced bone age [1].

A three-tier clinical decision framework for evaluating a child under 12 presenting with signs of androgen excess:

Tier 1 (Rule out endogenous causes first). Order serum testosterone, LH, FSH, DHEA-S, 17-hydroxyprogesterone, and a bone age X-ray before assuming exogenous exposure. Premature adrenarche, congenital adrenal hyperplasia, and gonadotropin-independent precocious puberty must be excluded [26].

Tier 2 (Investigate the home environment). If endogenous causes are ruled out, ask specifically about testosterone products in the household: gels, patches, injections, or compounded creams. Request that all household members using testosterone be evaluated and counseled on exposure prevention.

Tier 3 (Manage ongoing virilization). Remove the exposure source. Most signs of virilization in young children plateau and partially regress once exogenous androgen is removed, but bone age advancement does not reverse. Follow bone age every 6 months until skeletal maturation normalizes [27].

Prescribing Protocols Used by Pediatric Endocrinologists

No FDA-approved pediatric dosing protocol exists for testosterone cypionate in children under 12. The protocols in current use are derived from expert consensus and small trials.

Micropenis Protocol (Neonates to Age 2)

Testosterone cypionate 25 mg intramuscularly every 4 weeks for 3 months. Bone age radiograph at baseline and 6 months post-treatment. Reassess penile length at 3 months. If no response by 3 months, reassess diagnosis and consider alternative etiologies [14].

CDGP Protocol (Ages 11 to 14, Extended to Age 10 in Rare Cases)

Testosterone cypionate 50 mg intramuscularly every 4 weeks for up to 6 months. Check serum testosterone trough before the third injection. Bone age X-ray at baseline and 6 months. After 6 months, stop treatment and reassess spontaneous pubertal progression over the next 6 months before considering a second course [3].

Confirmed Hypogonadism (Any Age Under 12, Rare)

Start at 25 mg intramuscularly every 4 weeks. Increase by 25 mg every 6 months based on clinical response and bone age trajectory. The goal is to mimic normal pubertal testosterone rise, not to achieve adult male levels [16].

Summary of Evidence Gaps and Research Priorities

The evidence base for testosterone cypionate in children under 12 is thin by the standards of any major therapeutic area. The following gaps are most clinically significant:

• No randomized controlled trial has compared testosterone cypionate against placebo in boys under age 10 with CDGP with final adult height as a primary endpoint.
• Pediatric pharmacokinetic data for intramuscular testosterone cypionate in children weighing under 30 kg are largely absent from the published literature.
• Long-term neurodevelopmental follow-up data beyond age 18 for boys treated with testosterone under age 10 do not exist in any published cohort.
• The dose threshold below which bone age advancement does not occur in children under 8 has not been established [28].

The Pediatric Endocrine Society has identified these gaps as research priorities. Clinicians considering any off-label use should discuss enrollment in registries such as the NCATS Rare Diseases Clinical Research Network when applicable.